Teva Pharmaceutical Industries saw its shares gain in pre-open trading after the company disclosed positive Phase 2a data for TEV ’408, an investigational anti-interleukin-15 antibody targeting celiac disease. The stock climbed 3.3% ahead of the market open as investors reacted to the clinical readout.
The Phase 2a trial met its primary endpoint, demonstrating both statistical significance and clinical meaningfulness in preventing gluten-induced intestinal damage compared with placebo at week 8. Teva said the treatment was well tolerated in the study population and that no emerging safety signals were observed.
Analysts and market participants noted the result carries additional strategic importance because TEV ’408 is already being advanced into a Phase 2b study for vitiligo. That positioning makes the molecule potentially relevant across multiple autoimmune indications, rather than as a single-condition asset.
TEV ’408 was developed in collaboration with Royalty Pharma, which has committed up to $500 million to support its clinical development. Teva hosted a dedicated investor call this morning to present and discuss the new data, an event that heightened investor attention and likely contributed to the pre-market move.
The surge in Teva shares occurred against a generally muted U.S. equity backdrop. The S&P 500 inched up 0.1%, the Dow Jones Industrial Average advanced 0.3%, and the Nasdaq slipped slightly, indicating the stock's gain was driven primarily by the company-specific pipeline news rather than broader market trends.
Teva's peers in the pharmaceutical sector did not report comparable company-specific catalysts on the same day, underscoring that the outperformance was tied to TEV ’408 rather than sector momentum. Market observers pointed to the clinical win as a fresh validation point in Teva's ongoing corporate transformation.
That transformation has included several notable developments for the company previously, including a Moody's investment-grade credit upgrade, an FDA priority review for ecopipam in Tourette syndrome, and an upward revision to full-year revenue guidance. Collectively, those items and the new TEV ’408 readout have brought the stock closer to its 52-week high.
Clear summary
TEV ’408 achieved its Phase 2a primary endpoint in celiac disease by preventing gluten-induced intestinal damage at week 8 and showed a favorable tolerability profile. The result amplifies the asset's multi-indication potential as it moves into Phase 2b for vitiligo and follows a funding commitment from Royalty Pharma.